Wechselwirkungen · Efavirenz Teva
Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-215300 · Präparat HOS-155418
The steady-state AUC, Cmax and Cmin of the active carbamazepine epoxide metabolite remained unchanged. Co-administration of higher doses of either efavirenz or carbamazepine has not been studied. Phenytoin, phenobarbital, and Interaction not studied. There is a When efavirenz is other anticonvulsants that are potential for reduction or increase in co-administered with an substrates of CYP450 isoenzymes the plasma concentrations of anticonvulsant that is a substrate phenytoin, phenobarbital and other of CYP450 isoenzymes, periodic anticonvulsants that are substrates of monitoring of anticonvulsant CYP450 isoenzymes when levels should be conducted. co-administered with efavirenz. Valproic acid/efavirenz No clinically significant effect on No dose adjustment is necessary (250 mg twice daily/600 mg once efavirenz pharmacokinetics. Limited for efavirenz. Patients should be daily) data suggest there is no clinically monitored for seizure control. significant effect on valproic acid pharmacokinetics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-03-03T18:18:00Z · SHA-256 d2c4a637bb18ba1e0c98c69218ce14671957659a5aa55fba40e74b1bf5620382 · Passage c428f274d76ddbf0d2b75fb067fd943a6acff83334ec2cf771db513fddb32737 · Zeichen 41896–43403 im Abschnitt